

Generics Global Industry Almanac 2019-2028

Industry Report | 2024-12-20 | 586 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$2995.00
- Site License (PDF) \$5990.00
- Enterprisewide license (PDF) \$8985.00

Report description:

Generics Global Industry Almanac 2019-2028

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.

- All market data and forecasts are adjusted for inflation and all currency conversions used in the creation of this report have been calculated using yearly annual average exchange rates.

- The global generics market recorded revenues of \$394.6 billion in 2023, representing a compound annual growth rate (CAGR) of 7.8% between 2018 and 2023.

- Market consumption volume increased with a CAGR of 1.4% between 2018 and 2023, to reach a total of 51.4% of total pharma volume in 2023.

- According to GlobalData, in 2023, Asia-Pacific accounting for a share of 47.7%, was the largest generics market globally. The dominance of the region is driven by its large-scale manufacturing capabilities, cost-competitive production, and robust supply

chain infrastructure.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the global generics market by value in 2023?
- What will be the size of the global generics market in 2028?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?

Table of Contents:

Table of Contents

- **1 EXECUTIVE SUMMARY**
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Competitive landscape
- 2 Introduction
- 2.1. What is this report about?
- 2.2. Who is the target reader?
- 2.3. How to use this report
- 2.4. Definitions
- 3 Global Generics
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in Asia-Pacific
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Generics in Europe

6.1. Market Overview 6.2. Market Data 6.3. Market Segmentation 6.4. Market outlook 6.5. Five forces analysis 7 Macroeconomic Indicators 7.1. Country data 8 Generics in France 8.1. Market Overview 8.2. Market Data 8.3. Market Segmentation 8.4. Market outlook 8.5. Five forces analysis 9 Macroeconomic Indicators 9.1. Country data 10 Generics in Germany 10.1. Market Overview 10.2. Market Data 10.3. Market Segmentation 10.4. Market outlook 10.5. Five forces analysis 11 Macroeconomic Indicators 11.1. Country data 12 Generics in Australia 12.1. Market Overview 12.2. Market Data 12.3. Market Segmentation 12.4. Market outlook 12.5. Five forces analysis 13 Macroeconomic Indicators 13.1. Country data 14 Generics in Brazil 14.1. Market Overview 14.2. Market Data 14.3. Market Segmentation 14.4. Market outlook 14.5. Five forces analysis 15 Macroeconomic Indicators 15.1. Country data 16 Generics in Canada 16.1. Market Overview 16.2. Market Data 16.3. Market Segmentation 16.4. Market outlook 16.5. Five forces analysis 17 Macroeconomic Indicators 17.1. Country data

18 Generics in China 18.1. Market Overview 18.2. Market Data 18.3. Market Segmentation 18.4. Market outlook 18.5. Five forces analysis 19 Macroeconomic Indicators 19.1. Country data 20 Generics in India 20.1. Market Overview 20.2. Market Data 20.3. Market Segmentation 20.4. Market outlook 20.5. Five forces analysis 21 Macroeconomic Indicators 21.1. Country data 22 Generics in Indonesia 22.1. Market Overview 22.2. Market Data 22.3. Market Segmentation 22.4. Market outlook 22.5. Five forces analysis 23 Macroeconomic Indicators 23.1. Country data 24 Generics in Italy 24.1. Market Overview 24.2. Market Data 24.3. Market Segmentation 24.4. Market outlook 24.5. Five forces analysis 25 Macroeconomic Indicators 25.1. Country data 26 Generics in Japan 26.1. Market Overview 26.2. Market Data 26.3. Market Segmentation 26.4. Market outlook 26.5. Five forces analysis 27 Macroeconomic Indicators 27.1. Country data 28 Generics in Mexico 28.1. Market Overview 28.2. Market Data 28.3. Market Segmentation 28.4. Market outlook 28.5. Five forces analysis 29 Macroeconomic Indicators

29.1. Country data 30 Generics in The Netherlands 30.1. Market Overview 30.2. Market Data 30.3. Market Segmentation 30.4. Market outlook 30.5. Five forces analysis 31 Macroeconomic Indicators 31.1. Country data 32 Generics in North America 32.1. Market Overview 32.2. Market Data 32.3. Market Segmentation 32.4. Market outlook 32.5. Five forces analysis 33 Generics in Russia 33.1. Market Overview 33.2. Market Data 33.3. Market Segmentation 33.4. Market outlook 33.5. Five forces analysis 34 Macroeconomic Indicators 34.1. Country data 35 Generics in Scandinavia 35.1. Market Overview 35.2. Market Data 35.3. Market Segmentation 35.4. Market outlook 35.5. Five forces analysis 36 Generics in Singapore 36.1. Market Overview 36.2. Market Data 36.3. Market Segmentation 36.4. Market outlook 36.5. Five forces analysis 37 Macroeconomic Indicators 37.1. Country data 38 Generics in South Africa 38.1. Market Overview 38.2. Market Data 38.3. Market Segmentation 38.4. Market outlook 38.5. Five forces analysis 39 Macroeconomic Indicators 39.1. Country data 40 Generics in South Korea 40.1. Market Overview

40.2. Market Data 40.3. Market Segmentation 40.4. Market outlook 40.5. Five forces analysis 41 Macroeconomic Indicators 41.1. Country data 42 Generics in Spain 42.1. Market Overview 42.2. Market Data 42.3. Market Segmentation 42.4. Market outlook 42.5. Five forces analysis 43 Macroeconomic Indicators 43.1. Country data 44 Generics in Turkey 44.1. Market Overview 44.2. Market Data 44.3. Market Segmentation 44.4. Market outlook 44.5. Five forces analysis 45 Macroeconomic Indicators 45.1. Country data 46 Generics in The United Kingdom 46.1. Market Overview 46.2. Market Data 46.3. Market Segmentation 46.4. Market outlook 46.5. Five forces analysis 47 Macroeconomic Indicators 47.1. Country data 48 Generics in The United States 48.1. Market Overview 48.2. Market Data 48.3. Market Segmentation 48.4. Market outlook 48.5. Five forces analysis 49 Macroeconomic Indicators 49.1. Country data 50 Company Profiles 50.1. Teva Pharmaceutical Industries Ltd 50.2. Viatris Inc 50.3. Sun Pharmaceutical Industries Ltd 50.4. Novartis AG 50.5. Sandoz Group AG 50.6. Hikma Pharmaceuticals Plc 50.7. Sanofi 50.8. Les Laboratoires Servier SAS

50.9. Stada Arzneimittel AG 50.10. Bayer AG 50.11. Lupin Ltd 50.12. Aspen Pharmacare Holdings Ltd 50.13. EMS SA 50.14. Eurofarma Laboratorios SA 50.15. Ache Laboratorios Farmaceuticos SA 50.16. Apotex Inc 50.17. Teva Canada Ltd 50.18. Sandoz Canada Inc 50.19. CSPC Pharmaceutical Group Ltd 50.20. Sino Biopharmaceutical Ltd 50.21. Hansoh Pharmaceutical Group Co Ltd 50.22. Dr. Reddy's Laboratories Ltd 50.23. Cipla Ltd 50.24. Aurobindo Pharma Ltd 50.25. PT Kalbe Farma Tbk 50.26. PT Indofarma Tbk 50.27. PT Sanbe Farma 50.28. PT Soho Global Health Tbk 50.29. Friulchem SpA 50.30. DOC Generici SRL 50.31. Recordati SpA 50.32. Daiichi Sankyo Co Ltd 50.33. Towa Pharmaceutical Co Ltd 50.34. Sawai Group Holdings Co Ltd 50.35. Toho Holdings Co Ltd 50.36. Laboratorios Silanes SA de CV 50.37. Pfizer Inc 50.38. Biocad 50.39. R-Pharm 50.40. Pharmstandard 50.41. AstraZeneca Plc 50.42. Bluefish Pharmaceuticals AB 50.43. Navamedic ASA 50.44. Novartis International AG 50.45. Beacons Pharmaceuticals Pte Ltd 50.46. Abbott Laboratories SA 50.47. Adcock Ingram Holdings Ltd 50.48. Dongkook Pharmaceutical Co Ltd 50.49. JW Holdings Corp 50.50. Hanmi Pharmaceuticals Co Ltd 50.51. Dong Wha Pharma Co Ltd 50.52. Esteve Pharmaceuticals SA 50.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS 50.54. Deva Holding AS 50.55. Sandoz Inc

51 Appendix

51.1. Methodology51.2. About MarketLine



Generics Global Industry Almanac 2019-2028

Industry Report | 2024-12-20 | 586 pages | MarketLine

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single user licence (PDF)		\$2995.00
	Site License (PDF)		\$5990.00
	Enterprisewide license (PDF)		\$8985.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-06
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com